Research Keyword: in vivo efficacy

Sandalwood Sesquiterpene (Z)-α-Santalol Exhibits In Vivo Efficacy Against Madurella mycetomatis in Galleria mellonella Larvae

mycolabadmin

Researchers tested sandalwood compounds against a fungal infection that causes a tropical disease called eumycetoma. Using a laboratory model with wax moth larvae infected with the fungus, they found that a specific compound called (Z)-α-santalol significantly extended the survival of infected larvae. This compound was more effective than current antifungal drugs and showed promise as a potential new treatment for this neglected tropical disease.

Read More »

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

mycolabadmin

This study tested a new antifungal drug called SF001 against a serious infection called fusariosis in mice. SF001 performed as well as the current standard treatment (amphotericin B) but with better safety profiles. The drug successfully reduced fungal infections in organs and improved survival rates in infected mice without showing signs of toxicity at higher doses.

Read More »

In vitro and in vivo efficacy of the antimycobacterial molecule SQ109 against the human pathogenic fungus, Cryptococcus neoformans

mycolabadmin

Researchers discovered that SQ109, an antimycobacterial drug, can effectively kill Cryptococcus fungi that cause serious brain infections in people with weakened immune systems. Unlike current treatments, cryptococcal cells don’t easily develop resistance to SQ109, and it works even better when combined with fluconazole. In mouse studies, SQ109 successfully treated cryptococcal infections, suggesting it could be a valuable new treatment option for patients worldwide, especially in resource-limited regions.

Read More »

Antifungal Effects of Pterostilbene on Candida albicans, Candida dubliniensis, and Microcosm Biofilms of Denture Stomatitis

mycolabadmin

Pterostilbene, a natural compound found in blueberries and grapes, has been shown to effectively kill Candida fungi that cause denture-related mouth infections. In laboratory tests, it successfully eliminated fungal cells and disrupted harmful biofilms within 8 hours. When tested in a living organism model, pterostilbene proved safe and reduced infection severity, suggesting it could be a promising natural alternative to conventional antifungal medications.

Read More »

Sandalwood Sesquiterpene (Z)-α-Santalol Exhibits In Vivo Efficacy Against Madurella mycetomatis in Galleria mellonella Larvae

mycolabadmin

Researchers tested sandalwood oil components against a fungal disease called eumycetoma that causes serious skin infections, especially in tropical regions. They found that one component called (Z)-α-santalol was highly effective at killing the fungus and extending survival in laboratory-infected moth larvae, while actually being relatively safe. This natural compound shows promise as a potential new treatment for this neglected disease that currently relies on expensive drugs that are only 40% effective.

Read More »

Antifungal activity and mechanism of novel peptide Glycine max antimicrobial peptide (GmAMP) against fluconazole-resistant Candida tropicalis

mycolabadmin

Scientists developed a new antimicrobial peptide called GmAMP that can effectively kill drug-resistant fungal infections caused by Candida tropicalis, a pathogen resistant to common antifungal medications. The peptide works by damaging the fungal cell membrane and is safe for human use. In laboratory tests using insect larvae, the peptide successfully treated infections and reduced the fungal burden, suggesting it could become a new treatment option for patients with resistant fungal infections.

Read More »

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

mycolabadmin

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Read More »
Scroll to Top